Burkitt's lymphoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Small non-cleaved cell lymphoma, also known as Burkitt lymphoma, is a very aggressive B-cell NHL that is characterized by the translocation and dysregulation of the c-myc gene on chromosome 8. Burkitt-like lymphoma with 11q aberration is a new provisional entity that does not have MYC rearrangements but is comparable to Burkitt lymphoma in terms of morphology, phenotype, and gene expression profiling, according to the 2016 World Health Organization (WHO) classification of lymphoid neoplasms. One to five% of cases are Burkitt lymphomas, which are non-Hodgkin lymphomas. BL affects Caucasians more frequently than people of African or Asian descent. The quick development of Burkitt lymphoma therapies, which demand medical attention, is a significant factor fueling the market's expansion. One of the human cancers with the fastest rate of growth, Burkitt lymphoma, is incredibly deadly if left untreated in its early stages.

Description

Small non-cleaved cell lymphoma, or Burkitt lymphoma, a very aggressive B-cell NHL, has a translocated and dysregulated copy of the c-myc gene on chromosome 8. Burkitt-like lymphoma with 11q aberration is a new provisional entity that lacks MYC rearrangements but resembles Burkitt lymphoma morphologically, to a significant extent phenotypically, and by gene expression profiling, according to the 2016 World Health Organization (WHO) classification of lymphoid neoplasms. Burkitt's lymphoma causes rapidly expanding masses of lymph node tumors to form in the chest and/or abdomen. In addition to the liver, spleen, and bone marrow, it has a strong propensity to spread to the brain and spinal cord. According to the Leukemia Foundation, Burkitt's lymphoma has a very aggressive course if left untreated, but modern combination chemotherapy regimens have a high response rate.

Burkitt's lymphoma (Epidemiology)

Burkitt lymphomas make up 1% to 5% of non-Hodgkin lymphomas. Caucasians are more frequently affected by BL than people with African or Asian ancestry. With a 3 to 4:1 male to female ratio, BL is more common in men than most other types of lymphoma. Between 3 and 6 cases per 100,000 young people occur in youth under the age of 18 each year. The only continents where the sporadic variant is present are North America and Europe, where the median diagnostic age is 45 years old. Sporadic BL is anticipated to have a 4 per 1 million children under the age of 16 annual incidence, compared to a 2.5 per 1 million adult incidences.

Burkitt's lymphoma -Current Market Size & Forecast Trends

The market for Burkitt lymphoma is expected to grow significantly, projected to increase from approximately USD 996.4 million in 2023 to around USD 2.63 billion by 2034, reflecting a strong growth trajectory. This expansion is driven by the rising incidence of Burkitt lymphoma, particularly in regions where it is endemic, such as equatorial Africa, and advancements in treatment options, including chemotherapy and targeted therapies. The increasing awareness of the disease and improvements in diagnostic techniques are also contributing factors to market growth. Additionally, ongoing research and development efforts aimed at enhancing treatment efficacy and patient outcomes are likely to further bolster the market landscape through 2035.

One of the main factors driving the market's growth is the rapid advancement of Burkitt lymphoma therapies that require medical attention. Burkitt lymphoma, one of the fastest-growing human cancers, is extremely lethal if untreated in the early stages. Since Burkitt lymphoma must be treated quickly, businesses are heavily funding R&D to develop extremely effective medications. The majority of businesses are vying for customers in the developing market, including XmAb13676, ADCT402, PCI-32765, Tisagenlecleucel and others that could propel the market upward.

Report Highlights

Burkitt's lymphoma - Current Market Trends

Burkitt's lymphoma - Current & Forecasted Cases across the G8 Countries

Burkitt's lymphoma - Market Opportunities and Sales Potential for Agents

Burkitt's lymphoma - Patient-based Market Forecast to 2035

Burkitt's lymphoma - Untapped Business Opportunities

Burkitt's lymphoma - Product Positioning Vis-a-vis Competitors' Products

Burkitt's lymphoma - KOLs Insight